Novo Nordisk's Dutch Court Victory and Buyback Push: A Two-Pronged Effort to Shore Up Investor Confidence

Novo Nordisk wins Dutch injunction against semaglutide spray compounder, advances 11.2B DKK buyback, while shares remain 27% below January peak.

The Danish pharmaceutical giant is fighting its battles on two distinct fronts — one in the courtroom, the other in the capital markets — as it seeks to steady a share price that remains well below its January peak.

In a notable legal development, a district court in The Hague has sided with Novo Nordisk against a Dutch compounder, issuing an injunction that halts the sale of a knock-off semaglutide nasal spray. The ruling against Ceban Ziekenhuisfarmacie B.V. found that the company had infringed on Novo Nordisk's supplementary protection certificate for semaglutide, the active ingredient in its blockbuster obesity and diabetes treatments.

The court's order extends beyond a simple sales ban. Ceban is now required to remove product listings, disclose information about its commercial supply chain, and cover Novo Nordisk's legal expenses. A particularly striking detail emerged from the ruling: semaglutide nasal sprays have not received regulatory approval from any health authority anywhere in the world.

The case adds to a growing list of legal actions Novo Nordisk has taken against producers of compounded GLP-1 products that operate outside traditional regulatory approval pathways. As demand for semaglutide-containing medications continues to surge, the company is clearly intent on defending its intellectual property with increasing vigor.

Buyback Program Marches On

On the shareholder front, Novo Nordisk continues to execute its share repurchase program with steady discipline. Through August 14, the company had bought back 28,884,179 B-shares at an average price of 279.80 Danish kroner, representing a transaction volume of approximately 8.08 billion kroner.

The company now holds 42,924,876 of its own B-shares as treasury shares, equivalent to 1.0 percent of its share capital. The program, which has a total volume of up to 11.2 billion kroner, is scheduled to run until February 1, 2027. Notably, August 14 also marked the ex-dividend date for the interim dividend on A- and B-shares, with the corresponding date for ADRs falling on August 17.

The buyback activity — executed at prices around 280 kroner, well below the current European trading level of approximately 39.95 euros — signals management's confidence in the company's valuation even as the operating environment has grown more challenging.

A Stock Caught Between Recovery and Reality

The share price tells a story of partial stabilization. The stock recently closed at 39.98 euros, up 1.0 percent on the day and 2.9 percent for the week. Yet the longer-term picture remains sobering: the shares are down 9.2 percent year-to-date and 18 percent over the past twelve months.

The gap to the 52-week high of 54.86 euros, reached in late January, still stands at 27 percent. At the same time, the stock has climbed 32 percent from its early March low of 30.25 euros — a reminder of just how volatile trading has been.

That volatility reflects a company navigating multiple crosscurrents simultaneously: legal battles over its core semaglutide franchise, a demanding U.S. market for GLP-1 products, and the ongoing task of returning capital to shareholders. The company is also working on other fronts, including a developing AI partnership with Amazon Web Services, as part of a broader effort to rebuild investor trust.

For Novo Nordisk, the central challenge in the months ahead remains balancing intellectual property protection, competitive pressure in its key U.S. market, and shareholder returns — all while the competitive landscape in the obesity space grows increasingly crowded. The Dutch court victory offers a degree of reassurance that the company will defend its patent estate, but whether that translates into sustained share price recovery will ultimately depend on how the broader competitive dynamics play out.